白介素Ⅱ／高聚金葡素胸腹腔注射治疗恶性胸腹液疗效分析

目的：总结白细胞介素Ⅱ（IL－2）／高聚金葡素（BM828）胸腹腔注射治疗恶性胸腹水疗效和毒副作用。方法：对47例合并胸腹液的恶性肿瘤病人采用白介素Ⅱ50万单位／高聚金葡素3000单位同时一胸腹腔注射，每周二次，每两周为一疗程。结果：总有效率87．5％，其中完全缓解79％，部分缓解8．5％，好转8．5％，无效4％，少部分病人出现寒战，发热、局部疼痛。分别占16％、23％、4％，未见心肝肾功能损害。结论：我们认为白细胞介素Ⅱ、高聚金葡素胸腹腔注射治疗恶性胸腹液疗效显著、安全、操作方便，毒副作用小，值得推广。     

复方苦参注射液与5-氟脲嘧啶对大肠癌LoVo细胞生长抑制的作用及其机制

目的 探讨复方苦参注射液与5-氟脲嘧啶对大肠癌LoVo细胞生长抑制的作用及其机制.方法 台盼蓝染色法测定药物对LoVo细胞抑制作用与时间和剂量的关系,用荧光显微镜、流式细胞仪和免疫印迹分析对药物作用进行检测.结果 Annexin V-FITC和PI双染细胞,复方苦参注射液(40μg/L)和5-Fu(5-氟脲嘧啶,12.5 mg/L)共同作用LoVo细胞24 h后,处于正常生长状态为64.3%,凋亡细胞占26.5%与单一使用药物组差异有统计学意义(P＜0.05).复方苦参注射液(40μgg/L)和5-Fu(12.5 mg/L)共同作用时首先激活Caspase-3和Caspase-9,而Caspase-8则是一个晚期事件.结论 复方苦参注射液和5-Fu对LoVo细胞的生长具有协同抑制作用.两种药物的共同作用与单一使用一种药物的作用机制不同.     

Results of an innovative bulking agent in patients with stress urinary incontinence who are not optimal candidates for mid‐urethral sling surgery

Aims

To assess the efficacy and safety of peri‐urethral bulking injections (PBI) with an innovative bulking material (PDMS‐U) in women with stress‐urinary incontinence (SUI) who are not optimal candidates for mid‐urethral sling surgery.

Methods

A prospective study was performed in women with SUI who, for several reasons, have a relative contraindication for a mid‐urethral sling procedure. These reasons include: (i) recurrent SUI after a prior SUI surgical procedure; (ii) a history of oncologic gynaecological surgery; (iii) a history of neurologic disease resulting in voiding problems; (iv) a maximal flow rate of less than 15 mL per second or; (v) women with a contraindication for surgery with general or regional anaesthesia. All women were treated with PBI consisting of PDMS‐U, a bulking agent that polymerizes in situ. The primary outcome was subjective improvement, defined as “a little better” to “very much better” on the PGI‐I. Secondary outcomes included objective cure, disease specific quality of life and adverse events.

Results

Subjective improvement was reported by 18 (90%) of the 20 included patients. The subjective cure rate was 56% and the objective cure rate was 65%. There was a statistically significant improvement of all domain scores of the UDI‐6, IIQ‐7, and PISQ‐12 at 6 months follow up. Abnormal post voiding residual volume (>150 mL) was the most common adverse event (40%), but persisted in only one patient, based on the patient's preference for a catheter.

Conclusions

PBI with PDMS‐U is a viable treatment option in women with a relative contra‐indication for mid‐urethral sling surgery.     

外贴跌打膏对静脉拔针后皮下瘀血治疗效果的观察

目的 探讨外贴跌打膏治疗静脉穿刺拔针后局部瘀血的疗效.方法 对我科2005年1月～2007年1月住院期间208例静脉穿刺拔针后皮下瘀血患者随机分为试验组107例和对照组101例,试验组实施护理干预,于拔针后瘀血部位外贴跌打膏;对照组采用传统热敷拔针后瘀血部位.观察皮下瘀血消散时间、疼痛持续时间.结果 两组皮下瘀血消散时间、疼痛持续时间比较有显著性差异(P《0.01).结论 外贴跌打膏能明显促进静脉穿刺拔针后所致皮下瘀血的吸收,缩短疼痛的时间,疼痛程度明显减轻,跌打膏具有取材方便,操作简单,效果好,患者活动不受限.     

动态浊度法检测5种中药注射液的内毒素含量

目的:通过特异性及非特异性鲎试剂(TAL)动态浊度法对5种中药注射液的内毒素含量进行检测,探讨该方法对中药注射液检测的适用性。方法:采用特异性及非特异性动态浊度试剂盒,对不同批次的鱼腥草注射液、双黄连注射液、清开灵注射液、葛根素注射液、香丹注射液进行检测。结果:无色的中药注射剂如鱼腥草注射剂、葛根素注射剂对检测干扰较少,非特异性及特异性动态比浊法对其无显著影响;对非单一成分,颜色较深的中药注射液,如清开灵、香丹、双黄连注射液,采用动态比浊法进行检测,干扰大,检测结果不稳定;清开灵注射剂采用特异性试剂盒进行检测能有效的消除干扰,但香丹、双黄连注射液仍不能消除干扰。结论:用特异性或非特异性动态浊度法可以检测鱼腥草和葛根素注射液中的内毒素含量,采用特异性动态浊度法可以检测清开灵注射液中内毒素含量,双黄连和香丹注射液的检测结果不稳定。     

中药注射剂溶血检查的两种方法比较

目的:常规体外试管法与分光光度法在中药注射剂溶血检查中的应用比较。方法:通过吸收波长、离心转速及温育时间的研究,建立了分光光度法测定溶血率的方法,并与常规体外试管法进行了3种中药注射剂溶血试验的结果对比。结果:分光光度法可以定量地测定中药注射剂的溶血程度,较常规体外试管法更能准确地判断药品的质量。结论:建议对于中药注射剂应使用分光光度法评价其溶血程度。